The European Medicines Agency (EMA) has given the green light to the use of Moderna's corona vaccine in children and adolescents aged twelve and over.
The responsible EMA committee recommended an extension of the approval on Friday.
The final decision now has to be made by the European Commission.
But this is a matter of form.
Moderna's “Spikevax” preparation would be the second corona vaccine that can also be administered to young people. At the end of May, Pfizer / BioNTech's vaccine was also approved for 12 to 17 year olds. Moderna's application was based on a study of 2,500 adolescents in the United States. According to the company, the effectiveness was 100 percent. The EMA experts assessed the relevant data from studies in Amsterdam on Friday as positive.